imatinib mesylate has been researched along with B-Cell Chronic Lymphocytic Leukemia in 34 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 16 (47.06) | 29.6817 |
| 2010's | 16 (47.06) | 24.3611 |
| 2020's | 2 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Baron, J; Fu, K; Hernandez-Ilizaliturri, F; Jani Sait, SN; Kashef, F; Przespolewski, ER; Thompson, J | 1 |
| Bhattacharya, M; Cronin, KA; de Claro, RA; Ehrlich, LA; Gormley, NJ; Howlader, N; Mariotto, AB; Richardson, NC; Sharon, E; Wood, AE | 1 |
| Bay, JO; Bezy, O; Chabrier, M; Jalenques, I; Mouret, MA | 1 |
| Grant, S; Hawkins, E; Kmieciak, M; Kolluri, A; Lin, H; Nguyen, T; Park, H | 1 |
| Gong, Y; Lin, J; Liu, X; Naren, D; Shi, F; Shi, R; Yan, T; Yang, X | 1 |
| Egan, D; Radich, J | 1 |
| Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A | 1 |
| Bhagavathi, S; Borromeo, V; Crisan, D; Desai, H | 1 |
| Altavilla, G; Arrigo, C; Pitini, V | 1 |
| Apostolidis, J; Baltadakis, I; Evangelou, K; Gorgoulis, VG; Harhalakis, N; Karakasis, D; Papadakis, V; Sfikakis, PP | 1 |
| Adil, SN; Kumar, S; Masood, N | 1 |
| Aloyz, R; Amrein, L; Assouline, S; Caplan, S; Desjardins, P; Egorin, MJ; Hebb, J; Panasci, L; Rousseau, C | 1 |
| Chu, DT | 1 |
| Allen, JC; Lin, K; Slupsky, JR; Talab, F; Zuzel, M | 1 |
| Aloyz, R; Amrein, L; Davidson, D; Miller, WH; Panasci, L; Petruccelli, LA; Shawi, M | 1 |
| Hattori, H; Karasuno, T; Kotake, T; Kuwayama, M | 1 |
| Aloyz, R; Amrein, L; Jean-Claude, B; Panasci, L; Rachid, Z; Soulières, D | 1 |
| Buda-Okreglak, EM; Cordaro, DV | 1 |
| Aloyz, R; Johnston, JB; Kumar, R; Yoon, JY | 1 |
| Guo, Y; Munoz, J | 1 |
| Levi, MM | 1 |
| Brendel, C; Burchert, A; Hochhaus, A; Kumari, A; Neubauer, A | 1 |
| Bianchino, G; D'Arena, G; D'Auria, F; Deaglio, S; Del Vecchio, L; Gemei, M; Grieco, V; Guariglia, R; Luciano, L; Mansueto, G; Martorelli, MC; Musto, P; Pietrantuono, G; Statuto, T; Villani, O | 1 |
| Clark, RE; Lin, K; Salim, R; Wang, L | 1 |
| Okamoto, S | 1 |
| Alaoui-Jamali, MA; Aloyz, R; Grzywacz, K; Loignon, M; Panasci, L; Xu, ZY | 1 |
| Ascani, S; Bonomini, S; Caramatti, C; Colla, S; Craviotto, L; Crugnola, M; De Celis, I; Giuliani, N; Hojden, M; Morandi, F; Rizzoli, V; Sabbatini, E; Sammarelli, G | 1 |
| Kikuchi, S; Kirito, K; Komatsu, N; Kunitama, M; Mori, M; Nagai, T; Ozawa, K; Uchida, M; Watanabe, T; Yoshida, K | 1 |
| Herbers, AH; Keuning, JJ | 1 |
| Chow, KU; Hofmann, W; Hofmann, WK; Nowak, D; Schneider, B | 1 |
| Aguillon, RA; Carson, DA; Castro, JE; Dicker, F; Fukuda, T; Kipps, TJ; Kitada, S; Motta, M; Prada, CE; Reed, JC; Sun, G; Wang, JY; Wu, C | 1 |
| Castro, JE; Dicker, F; Fukuda, T; Kater, AP; Kipps, TJ; Prada, CE; Sun, G; Wang, JY | 1 |
| Cawley, JC; Dennett, S; Duckworth, AD; Glenn, MA; Harris, RJ; Lin, K; Slupsky, JR; Zuzel, M | 1 |
| Apperley, JF; Chaidos, A; Kanfer, E | 1 |
9 review(s) available for imatinib mesylate and B-Cell Chronic Lymphocytic Leukemia
| Article | Year |
|---|---|
[Impact of depressive disorders on adherence to oral anti-cancer treatment].
Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Breast Neoplasms; Depressive Disorder; Female; Health Care Costs; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Medical Oncology; Medication Adherence; Piperazines; Pyrimidines; Tamoxifen; Treatment Outcome | 2013 |
Making the diagnosis, the tools, and risk stratification: More than just BCR-ABL.
Topics: Clinical Trials as Topic; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferons; Leukemia, Lymphocytic, Chronic, B-Cell; Protein Kinase Inhibitors; Risk Assessment | 2016 |
[Novel medical treatment modalities in hematology].
Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine | 2008 |
Old disease, new targets. Part-II, haematological malignancies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Drug Costs; Graft vs Host Disease; Hematologic Neoplasms; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Rituximab; Time Factors | 2009 |
[Clinical manifestation of targeted drugs in individualized therapy of malignant tumors].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclophosphamide; Doxorubicin; Drug Delivery Systems; ErbB Receptors; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Lymphoma, Large B-Cell, Diffuse; Mutation; Neoplasms; Piperazines; Prednisone; Pyrimidines; Pyrroles; Remission Induction; Rituximab; Sunitinib; Vincristine | 2010 |
[A case of chronic myeloid leukemia occurring during treatment for chronic lymphocytic leukemia].
Topics: Aged; Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Female; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms, Second Primary; Piperazines; Pyrimidines; Vidarabine | 2011 |
[Evidence-based therapy for chronic leukemia].
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Enzyme Inhibitors; Evidence-Based Medicine; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Rituximab; Transplantation, Homologous; Vidarabine | 2003 |
Co-existence of Philadelphia chromosome positive acute megakaryoblastic and B-lymphoblastic mixed blast crisis of chronic myeloid leukemia with chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Burkitt Lymphoma; Cytarabine; Daunorubicin; Female; Humans; Imatinib Mesylate; Immunophenotyping; Karyotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Megakaryoblastic, Acute; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms, Multiple Primary; Piperazines; Pyrimidines; Remission Induction | 2004 |
Risk assessment in haemotopoietic stem cell transplantation: disease and disease stage.
Topics: Acute Disease; Adult; Benzamides; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasm Staging; Neoplasms; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Pyrimidines; Recurrence; Risk Assessment; Survival Analysis; Transplantation, Homologous | 2007 |
1 trial(s) available for imatinib mesylate and B-Cell Chronic Lymphocytic Leukemia
| Article | Year |
|---|---|
A phase I study of imatinib mesylate in combination with chlorambucil in previously treated chronic lymphocytic leukemia patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chlorambucil; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyrimidines; Rad51 Recombinase; Recombination, Genetic; Treatment Outcome; Vidarabine | 2011 |
24 other study(ies) available for imatinib mesylate and B-Cell Chronic Lymphocytic Leukemia
| Article | Year |
|---|---|
Concomitant Venetoclax and Imatinib for Comanaging Chronic Lymphocytic Leukemia and Chronic Myeloid Leukemia: A Case Report.
Topics: Antineoplastic Agents; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2023 |
The Impact of Improved Treatments on Survival of Adult U.S. Leukemia Patients: 1990-2018.
Topics: Adult; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Registries | 2023 |
Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells.
Topics: Amino Acid Substitution; Aniline Compounds; Animals; Antineoplastic Agents; Benzamides; Benzodiazepinones; Checkpoint Kinase 1; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Lymphocytic, Chronic, B-Cell; MAP Kinase Kinase 1; MAP Kinase Signaling System; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mutation, Missense; Myeloid Cell Leukemia Sequence 1 Protein; Nitriles; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein Kinases; Pyrazoles; Pyrimidines; Quinolines; Xenograft Model Antitumor Assays | 2015 |
The antileukemia effect of metformin in the Philadelphia chromosome-positive leukemia cell line and patient primary leukemia cell.
Topics: Antineoplastic Agents; Autophagy; Benzamides; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; MAP Kinase Signaling System; Metformin; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Tumor Cells, Cultured | 2015 |
Case report and literature review: a rare patient with chronic myeloid leukemia and chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Agents; Benzamides; Flow Cytometry; Humans; Imatinib Mesylate; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Polymerase Chain Reaction; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction | 2008 |
Dasatinib induces a response in chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blood Cell Count; Dasatinib; Female; Fusion Proteins, bcr-abl; Hemorrhage; Humans; Imatinib Mesylate; Jejunal Diseases; Leukemia, Lymphocytic, Chronic, B-Cell; Liver Neoplasms; Magnetic Resonance Imaging; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Rituximab; src-Family Kinases; Thiazoles; Tomography, X-Ray Computed; Vidarabine | 2009 |
Is imatinib mesylate a promising drug in scleroderma due to extensive chronic graft-versus-host disease?
Topics: Benzamides; Chronic Disease; Female; Graft vs Host Disease; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Piperazines; Pyrimidines; Scleroderma, Systemic; Treatment Outcome | 2009 |
c-Abl regulates Mcl-1 gene expression in chronic lymphocytic leukemia cells.
Topics: Benzamides; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Myeloid Cell Leukemia Sequence 1 Protein; Piperazines; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; RNA, Messenger; RNA, Small Interfering; STAT3 Transcription Factor; Tumor Cells, Cultured | 2011 |
Dual inhibition of the homologous recombinational repair and the nonhomologous end-joining repair pathways in chronic lymphocytic leukemia therapy.
Topics: Antineoplastic Agents, Alkylating; B-Lymphocytes; Benzamides; Blotting, Western; Chlorambucil; Comet Assay; DNA-Activated Protein Kinase; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Recombination, Genetic; Tumor Cells, Cultured | 2011 |
ZRF4, a combi-molecule with increased efficacy as compared with the individual components in chronic lymphocytic leukemia lymphocytes in vitro.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Cell Proliferation; Chlorambucil; DNA Damage; Humans; Imatinib Mesylate; In Vitro Techniques; Leukemia, Lymphocytic, Chronic, B-Cell; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-abl; Pyrimidines; Triazenes; Tumor Cells, Cultured | 2011 |
Simultaneous chronic myeloid leukemia and chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasms, Multiple Primary; Piperazines; Pyrimidines | 2011 |
Response of concomitant chronic myelogenous leukemia and chronic lymphocytic leukemia to imatinib mesylate.
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Treatment Outcome | 2011 |
Leukocytosis: the mysteries within.
Topics: Aged; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Leukocytosis; Male; Piperazines; Pyrimidines; Remission Induction | 2012 |
Clinical molecular medicine has finally arrived.
Topics: Benzamides; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction | 2011 |
Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Benzamides; Blotting, Western; Bone Marrow; Colony-Forming Units Assay; DNA Mismatch Repair; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Longitudinal Studies; Male; Mice; Mice, Inbred C57BL; Middle Aged; Piperazines; Prognosis; Pyrimidines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2012 |
Chronic lymphocytic leukemia after chronic myeloid leukemia in the same patient: two different genomic events and a common treatment?
Topics: Aged, 80 and over; Antineoplastic Agents; Benzamides; Dasatinib; Female; Flow Cytometry; Genome, Human; Humans; Imatinib Mesylate; Immunophenotyping; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoid Progenitor Cells; Myeloid Progenitor Cells; Neoplasms, Second Primary; Neoplastic Stem Cells; Piperazines; Pyrimidines; Thiazoles | 2012 |
Chronic lymphocytic leukaemia developing in the course of chronic myeloid leukaemia.
Topics: Benzamides; Clone Cells; Disease Progression; Female; Gene Rearrangement; Humans; Imatinib Mesylate; Immunoglobulin Heavy Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Middle Aged; Neoplasms, Second Primary; Philadelphia Chromosome; Piperazines; Pyrimidines | 2002 |
Imatinib sensitizes CLL lymphocytes to chlorambucil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Cycle; Chlorambucil; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Phosphorylation; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyrimidines; Rad51 Recombinase; Tumor Cells, Cultured | 2004 |
Erythropoietin overcomes imatinib-induced apoptosis and induces erythroid differentiation in TF-1/bcr-abl cells.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Benzamides; Cell Differentiation; Cell Line, Tumor; Erythropoietin; Fusion Proteins, bcr-abl; Granulocyte-Macrophage Colony-Stimulating Factor; Hemoglobins; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Proteins; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2004 |
Staging for CLL-type non-Hodgkin's lymphoma reveals a gastrointestinal stromal tumour.
Topics: Aged; Benzamides; Biopsy, Needle; Diagnosis, Differential; Follow-Up Studies; Gastrointestinal Stromal Tumors; Gastroscopy; Humans; Imatinib Mesylate; Immunohistochemistry; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Neoplasm Staging; Piperazines; Pyrimidines; Risk Assessment; Stomach Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2005 |
Imatinib induces apoptosis in CLL lymphocytes with high expression of Par-4.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Benzamides; Humans; Imatinib Mesylate; In Vitro Techniques; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Piperazines; Pyrimidines | 2005 |
Thymidine-phosphorothioate oligonucleotides induce activation and apoptosis of CLL cells independently of CpG motifs or BCL-2 gene interference.
Topics: Amino Acid Chloromethyl Ketones; Apoptosis; B-Lymphocytes; Benzamides; BH3 Interacting Domain Death Agonist Protein; Caspases; Cell Survival; CpG Islands; Drug Screening Assays, Antitumor; Enzyme Activation; Genes, bcl-2; Humans; Imatinib Mesylate; In Vitro Techniques; Leukemia, Lymphocytic, Chronic, B-Cell; Oligodeoxyribonucleotides; Organothiophosphorus Compounds; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-abl; Pyrimidines; Structure-Activity Relationship; Thymidine; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Up-Regulation | 2006 |
CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53.
Topics: Apoptosis; Benzamides; BH3 Interacting Domain Death Agonist Protein; CD40 Antigens; CD40 Ligand; Cell Count; DNA-Binding Proteins; fas Receptor; Gene Expression Regulation, Leukemic; HeLa Cells; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph Nodes; Nuclear Proteins; Piperazines; Proto-Oncogene Proteins c-abl; Pyrimidines; Tumor Cells, Cultured; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2006 |
c-Abl expression in chronic lymphocytic leukemia cells: clinical and therapeutic implications.
Topics: Antineoplastic Agents; Apoptosis; B-Lymphocytes; Benzamides; Genes, Immunoglobulin Heavy Chain; Humans; Imatinib Mesylate; Immunoglobulin Variable Region; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; NF-kappa B; Piperazines; Protein Isoforms; Proto-Oncogene Proteins c-abl; Pyrimidines; ZAP-70 Protein-Tyrosine Kinase | 2006 |